Phosphorus magnetic resonance spectroscopy: Brain pathologies applications;Spectroscopie du phosphore 31 par résonance magnétique: Applications en pathologies cérébrales

Journal of Neuroradiology

Volumn 37, Issue 2, 2010, Pages 73-82

  Menuel, C ^a   Guillevin, R ^a   Costalat, R ^b   Perrin, M ^c   Sahli Amor, M ^a   Martin Duverneuil, N ^a   Chiras, J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Université Pierre et Marie Curie   (France)

^c GE HEALTHCARE   (France)

Author keywords

Cerebral metabolism; Degenerative disease; Glioma; Metabolic disease; Multinuclear magnetic resonance spectroscopy; Phosphorus 31

Indexed keywords

BRAIN DEGENERATION; BRAIN DISEASE; BRAIN METABOLISM; BRAIN TUMOR; HUMAN; IN VIVO STUDY; MAGNETIC FIELD; MATHEMATICAL MODEL; METABOLIC DISORDER; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REVIEW; SIGNAL NOISE RATIO;

BRAIN; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS ISOTOPES;

EID: 77952670579     PISSN: 01509861     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurad.2009.07.001     Document Type: Review

References (57)

1. 31P nuclear magnetic resonance spectroscopy. Neurology 1985, 35(6):781-788.
2. Pellerin L. Brain energetics (thought needs food). Curr Opin Clin Nutr Metab Care 2008, 11(6):701-705.
3. 31P-n.m.r. spectroscopy, and its implications for metabolic control. A comparison of 31P-n. m. r. spectroscopy (in vivo and in vitro) with chemical and enzymic determinations of ATP, ADP and Pi. Biochem J 1985, 229(1):141-151.
4. 31P-NMR studies of a human tumour in situ. Lancet 1983, 1(8339):1435-1436.
5. Belardelli F., Proietti E., Ciolli V., Sestili P., Carpinelli G., Di Vito M., et al. Interleukin-1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor alpha or beta. Int J Cancer 1989, 44(1):116-123.
6. Podo F., Carpinelli G., Di Vito M., Giannini M., Proietti E., Fiers W., et al. Nuclear magnetic resonance analysis of tumor necrosis factor-induced alterations of phospholipid metabolites and pH in Friend leukemia cell tumors and fibrosarcomas in mice. Cancer Res 1987, 47(24 Pt 1):6481-6489.
7. 31P-nuclear magnetic resonance analysis of interferon-induced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. Cancer Res 1986, 46(6):2849-2857.
8. Guillevin R., Menuel C., Duffau H., Kujas M., Capelle L., Aubert A., et al. Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol 2008, 87(2):181-187.
9. Franconi F., Chapon C., Lemaire L., Lehmann V., Barantin L., Akoka S. Quantitative MR renography using a calibrated internal signal (ERETIC). Magn Reson Imaging 2002, 20(8):587-592.
10. Purpura D.P. Dendritic differentiation in human cerebral cortex: normal and aberrant developmental patterns. Adv Neurol 1975, 12:91-134.
11. Purpura D.P. Normal and aberrant neuronal development in the cerebral cortex of human fetus and young infant. UCLA Forum Med Sci 1975, (18):141-169.
12. Purves D., Lichtman J.W. Elimination of synapses in the developing nervous system. Science 1980, 210(4466):153-157.
13. Dobbing J., Sands J. Quantitative growth and development of human brain. Arch Dis Child 1973, 48(10):757-767.
14. Volpe J.J. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol 2009, 8(1):110-124.
15. Van der Knaap M.S., Valk J. MR imaging of the various stages of normal myelination during the first year of life. Neuroradiology 1990, 31(6):459-470.
16. Van der Knaap M.S., Valk J., Bakker C.J., Schooneveld M., Faber J.A., Willemse J., et al. Myelination as an expression of the functional maturity of the brain. Dev Med Child Neurol 1991, 33(10):849-857.
17. Barkovich A.J., Kjos B.O., Jackson D.E., Norman D. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. Radiology 1988, 166(1 Pt 1):173-180.
18. Norton W.T., Poduslo S.E. Myelination in rat brain: changes in myelin composition during brain maturation. J Neurochem 1973, 21(4):759-773.
19. Cady E.B. Quantitative combined phosphorus and proton PRESS of the brains of newborn human infants. Magn Reson Med 1995, 33(4):557-563.
20. Azzopardi D., Wyatt J.S., Hamilton P.A., Cady E.B., Delpy D.T., Hope P.L., et al. Phosphorus metabolites and intracellular pH in the brains of normal and small for gestational age infants investigated by magnetic resonance spectroscopy. Pediatr Res 1989, 25(5):440-444.
21. Cady E.B., Costello A.M., Dawson M.J., Delpy D.T., Hope P.L., Reynolds E.O., et al. Non-invasive investigation of cerebral metabolism in newborn infants by phosphorus nuclear magnetic resonance spectroscopy. Lancet 1983, 1(8333):1059-1062.
22. Van der Knaap M.S., van der Grond J., van Rijen P.C., Faber J.A., Valk J., Willemse K. Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain. Radiology 1990, 176(2):509-515.
23. Dawson R.M., Miller E., Jungalwala F.B. Turnover and exchange of phospholipids in the membranes of the nervous system. Biochem J 1972, 128(1):18P.
24. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations. J Neuropathol Exp Neurol 1987, 46(4):419-430.
25. Tofts P., Wray S. Changes in brain phosphorus metabolites during the post-natal development of the rat. J Physiol 1985, 359:417-429.
26. Hanaoka S., Takashima S., Morooka K. Study of the maturation of the child's brain using 31P-MRS. Pediatr Neurol 1998, 18(4):305-310.
27. Buchli R., Duc C.O., Martin E., Boesiger P. Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part I: Cerebrum, cerebellum, cerebral gray and white matter. Magn Reson Med 1994, 32(4):447-452.
28. Tsuji M.K., Mulkern R.V., Cook C.U., Meyers R.L., Holtzman D. Relative phosphocreatine and nucleoside triphosphate concentrations in cerebral gray and white matter measured in vivo by 31P nuclear magnetic resonance. Brain Res 1996, 707(2):146-154.
29. 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia. Biol Psychiatry 1992, 32(1):26-32.
30. 31P-MRS chemical shift imaging at 4 Tesla. Psychiatry Res 2006, 146(2):127-135.
31. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophr Bull 1993, 19(1):35-53.
32. Shioiri T., Kato T., Inubushi T., Murashita J., Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res 1994, 55(4):223-235.
33. Barbiroli B., Martinelli P., Patuelli A., Lodi R., Iotti S., Cortelli P., et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord 1999, 14(3):430-435.
34. Hoang T.Q., Bluml S., Dubowitz D.J., Moats R., Kopyov O., Jacques D., et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998, 50(4):1033-1040.
35. 31P spectroscopy study. Psychopharmacology (Berl) 2005, 180(2):359-365.
36. 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab 1993, 13(3):469-474.
37. Eleff S.M., Barker P.B., Blackband S.J., Chatham J.C., Lutz N.W., Johns D.R., et al. Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine. Ann Neurol 1990, 27(6):626-630.
38. Arnold D.L., Taylor D.J., Radda G.K. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol 1985, 18(2):189-196.
39. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999, 12(7):413-439.
40. Hubesch B., Sappey-Marinier D., Roth K., Meyerhoff D.J., Matson G.B., Weiner M.W. P-31 MR spectroscopy of normal human brain and brain tumors. Radiology 1990, 174(2):401-409.
41. Berkich D.A., Ola M.S., Cole J., Sweatt A.J., Hutson S.M., LaNoue K.F. Mitochondrial transport proteins of the brain. J Neurosci Res 2007, 85(15):3367-3377.
42. Maintz D., Heindel W., Kugel H., Jaeger R., Lackner K.J. Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumours. NMR Biomed 2002, 15(1):18-27.
43. Rutter A., Hugenholtz H., Saunders J.K., Smith I.C. One-dimensional phosphorus-31 chemical shift imaging of human brain tumors. Invest Radiol 1995, 30(6):359-366.
44. Hossmann K.A., Linn F., Okada Y. Bioluminescence and fluoroscopic imaging of tissue pH and metabolites in experimental brain tumors of cat. NMR Biomed 1992, 5(5):259-264.
45. Okada Y., Kloiber O., Hossmann K.A. Regional metabolism in experimental brain tumors in cats: relationship with acid/base, water, and electrolyte homeostasis. J Neurosurg 1992, 77(6):917-926.
46. Karczmar G.S., Meyerhoff D.J., Boska M.D., Hubesch B., Poole J., Matson G.B., et al. P-31 spectroscopy study of response of superficial human tumors to therapy. Radiology 1991, 179(1):149-153.
47. Hirakawa K., Naruse S., Higuchi T., Horikawa Y., Tanaka C., Ebisu T. The investigation of experimental brain tumours using 31P-MRS and 1H-MRI. Acta Neurochir Suppl (Wien) 1988, 43:140-144.
48. Hope P.L., Costello A.M., Cady E.B., Delpy D.T., Tofts P.S., Chu A., et al. Cerebral energy metabolism studied with phosphorus NMR spectroscopy in normal and birth-asphyxiated infants. Lancet 1984, 2(8399):366-370.
49. Laptook A.R., Corbett R.J., Uauy R., Mize C., Mendelsohn D., Nunnally R.L. Use of 31P magnetic resonance spectroscopy to characterize evolving brain damage after perinatal asphyxia. Neurology 1989, 39(5):709-712.
50. Azzopardi D., Wyatt J.S., Cady E.B., Delpy D.T., Baudin J., Stewart A.L., et al. Prognosis of newborn infants with hypoxic-ischemic brain injury assessed by phosphorus magnetic resonance spectroscopy. Pediatr Res 1989, 25(5):445-451.
51. Cady E.B. Magnetic resonance spectroscopy in neonatal hypoxic-ischaemic insults. Childs Nerv Syst 2001, 17(3):145-149.
52. Boska M.D., Welch K.M., Barker P.B., Nelson J.A., Schultz L. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 2002, 58(8):1227-1233.
53. Lodi R., Iotti S., Cortelli P., Pierangeli G., Cevoli S., Clementi V., et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 2001, 54(4):437-441.
54. Montagna P. Magnetic resonance spectroscopy in migraine. Cephalalgia 1995, 15(4):323-327.
55. Schulz U.G., Blamire A.M., Corkill R.G., Davies P., Styles P., Rothwell P.M. Association between cortical metabolite levels and clinical manifestations of migrainous aura: an MR-spectroscopy study. Brain 2007, 130(Pt 12):3102-3110.
56. Aubert A., Costalat R. A model of the coupling between brain electrical activity, metabolism, and hemodynamics: application to the interpretation of functional neuroimaging. Neuroimage 2002, 17(3):1162-1181.
57. Aubert A., Pellerin L., Magistretti P., Costalat R. A coherent neurobiological framework for functional neuroimaging provided by a model integrating compartmentalized energy metabolism. Proc Natl Sci U S A 2007, 104(10):4188-4193.